Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

A New In Vivo Model to Study Protective Immunity to Zika Virus Infection in Mice With Intact Type I Interferon Signaling.

Nazerai L, Schøller AS, Rasmussen POS, Buus S, Stryhn A, Christensen JP, Thomsen AR.

Front Immunol. 2018 Mar 22;9:593. doi: 10.3389/fimmu.2018.00593. eCollection 2018.

2.

Cytomegalovirus-specific T-cells are associated with immune senescence, but not with systemic inflammation, in people living with HIV.

Ballegaard V, Brændstrup P, Pedersen KK, Kirkby N, Stryhn A, Ryder LP, Gerstoft J, Nielsen SD.

Sci Rep. 2018 Feb 28;8(1):3778. doi: 10.1038/s41598-018-21347-4.

3.

Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection.

Adland E, Hill M, Lavandier N, Csala A, Edwards A, Chen F, Radkowski M, Kowalska JD, Paraskevis D, Hatzakis A, Valenzuela-Ponce H, Pfafferott K, Williams I, Pellegrino P, Borrow P, Mori M, Rockstroh J, Prado JG, Mothe B, Dalmau J, Martinez-Picado J, Tudor-Williams G, Frater J, Stryhn A, Buus S, Teran GR, Mallal S, John M, Buchbinder S, Kirk G, Martin J, Michael N, Fellay J, Deeks S, Walker B, Avila-Rios S, Cole D, Brander C, Carrington M, Goulder P.

J Virol. 2018 Jan 30;92(4). pii: e01685-17. doi: 10.1128/JVI.01685-17. Print 2018 Feb 15.

4.

Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.

Kongsgaard M, Bassi MR, Rasmussen M, Skjødt K, Thybo S, Gabriel M, Hansen MB, Christensen JP, Thomsen AR, Buus S, Stryhn A.

Sci Rep. 2017 Apr 6;7(1):662. doi: 10.1038/s41598-017-00798-1.

5.

HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer+ Gag-Specific CD4+ T Cells in Chronic Clade C HIV-1 Infection.

Laher F, Ranasinghe S, Porichis F, Mewalal N, Pretorius K, Ismail N, Buus S, Stryhn A, Carrington M, Walker BD, Ndung'u T, Ndhlovu ZM.

J Virol. 2017 Mar 13;91(7). pii: e02477-16. doi: 10.1128/JVI.02477-16. Print 2017 Apr 1.

6.

Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.

Bassi MR, Larsen MA, Kongsgaard M, Rasmussen M, Buus S, Stryhn A, Thomsen AR, Christensen JP.

PLoS Negl Trop Dis. 2016 Feb 17;10(2):e0004464. doi: 10.1371/journal.pntd.0004464. eCollection 2016 Feb.

7.

Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification.

Andreatta M, Karosiene E, Rasmussen M, Stryhn A, Buus S, Nielsen M.

Immunogenetics. 2015 Nov;67(11-12):641-50. doi: 10.1007/s00251-015-0873-y. Epub 2015 Sep 29.

8.

CD8+ TCR Bias and Immunodominance in HIV-1 Infection.

Kløverpris HN, McGregor R, McLaren JE, Ladell K, Harndahl M, Stryhn A, Carlson JM, Koofhethile C, Gerritsen B, Keşmir C, Chen F, Riddell L, Luzzi G, Leslie A, Walker BD, Ndung'u T, Buus S, Price DA, Goulder PJ.

J Immunol. 2015 Jun 1;194(11):5329-45. doi: 10.4049/jimmunol.1400854. Epub 2015 Apr 24.

9.

CD8+ T cells complement antibodies in protecting against yellow fever virus.

Bassi MR, Kongsgaard M, Steffensen MA, Fenger C, Rasmussen M, Skjødt K, Finsen B, Stryhn A, Buus S, Christensen JP, Thomsen AR.

J Immunol. 2015 Feb 1;194(3):1141-53. doi: 10.4049/jimmunol.1402605. Epub 2014 Dec 24.

10.

Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule.

Rasmussen M, Harndahl M, Stryhn A, Boucherma R, Nielsen LL, Lemonnier FA, Nielsen M, Buus S.

J Immunol. 2014 Nov 15;193(10):4790-802. doi: 10.4049/jimmunol.1401689. Epub 2014 Oct 13.

11.

Programmed death-1 expression on HIV-1-specific CD8+ T cells is shaped by epitope specificity, T-cell receptor clonotype usage and antigen load.

Kløverpris HN, McGregor R, McLaren JE, Ladell K, Stryhn A, Koofhethile C, Brener J, Chen F, Riddell L, Graziano L, Klenerman P, Leslie A, Buus S, Price DA, Goulder P.

AIDS. 2014 Sep 10;28(14):2007-21.

12.

Identification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2.

Braendstrup P, Mortensen BK, Justesen S, Osterby T, Rasmussen M, Hansen AM, Christiansen CB, Hansen MB, Nielsen M, Vindeløv L, Buus S, Stryhn A.

PLoS One. 2014 Apr 23;9(4):e94892. doi: 10.1371/journal.pone.0094892. eCollection 2014.

13.

Ex vivo tetramer staining and cell surface phenotyping for early activation markers CD38 and HLA-DR to enumerate and characterize malaria antigen-specific CD8+ T-cells induced in human volunteers immunized with a Plasmodium falciparum adenovirus-vectored malaria vaccine expressing AMA1.

Schwenk R, Banania G, Epstein J, Kim Y, Peters B, Belmonte M, Ganeshan H, Huang J, Reyes S, Stryhn A, Ockenhouse CF, Buus S, Richie TL, Sedegah M.

Malar J. 2013 Oct 29;12:376. doi: 10.1186/1475-2875-12-376.

14.

MHC class II tetramers made from isolated recombinant α and β chains refolded with affinity-tagged peptides.

Braendstrup P, Justesen S, Osterbye T, Nielsen LL, Mallone R, Vindeløv L, Stryhn A, Buus S.

PLoS One. 2013 Sep 2;8(9):e73648. doi: 10.1371/journal.pone.0073648. eCollection 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/97cabee9-2a2a-4bd6-a417-a2075e56a8d4. PLoS One. 2013;8(12). doi:10.1371/annotation/9375e7cb-92f1-4a83-adaf-c11f284ceee0.

15.

Nef-specific CD8+ T cell responses contribute to HIV-1 immune control.

Adland E, Carlson JM, Paioni P, Kløverpris H, Shapiro R, Ogwu A, Riddell L, Luzzi G, Chen F, Balachandran T, Heckerman D, Stryhn A, Edwards A, Ndung'u T, Walker BD, Buus S, Goulder P, Matthews PC.

PLoS One. 2013 Sep 2;8(9):e73117. doi: 10.1371/journal.pone.0073117. eCollection 2013.

16.

HIV subtype influences HLA-B*07:02-associated HIV disease outcome.

Kløverpris HN, Adland E, Koyanagi M, Stryhn A, Harndahl M, Matthews PC, Shapiro R, Walker BD, Ndung'u T, Brander C, Takiguchi M, Buus S, Goulder P.

AIDS Res Hum Retroviruses. 2014 May;30(5):468-75. doi: 10.1089/AID.2013.0197. Epub 2013 Oct 4.

17.

HLA-specific intracellular epitope processing shapes an immunodominance pattern for HLA-B*57 that is distinct from HLA-B*58:01.

Kløverpris HN, Stryhn A, Harndahl M, Payne R, Towers GJ, Chen F, Riddell L, Walker BD, Ndung'u T, Leslie A, Buus S, Goulder P.

J Virol. 2013 Oct;87(19):10889-94. doi: 10.1128/JVI.01122-13. Epub 2013 Jul 17.

18.

Qualitative and quantitative analysis of adenovirus type 5 vector-induced memory CD8 T cells: not as bad as their reputation.

Steffensen MA, Holst PJ, Steengaard SS, Jensen BA, Bartholdy C, Stryhn A, Christensen JP, Thomsen AR.

J Virol. 2013 Jun;87(11):6283-95. doi: 10.1128/JVI.00465-13. Epub 2013 Mar 27.

19.

HLA-A*68:02-restricted Gag-specific cytotoxic T lymphocyte responses can drive selection pressure on HIV but are subdominant and ineffective.

Kløverpris HN, Stryhn A, Harndahl M, Carlson JM, Leslie AJ, Chen F, Riddell L, Mulenga J, Walker BD, Ndung'u T, Buus S, Goulder P.

AIDS. 2013 Jul 17;27(11):1717-23. doi: 10.1097/QAD.0b013e32836146cd.

PMID:
23525031
20.

Peptide pool immunization and CD8+ T cell reactivity.

Rasmussen SB, Harndahl MN, Stryhn A, Buus S, Claesson MH.

Immunol Lett. 2013 Mar;151(1-2):48-53. doi: 10.1016/j.imlet.2013.02.006. Epub 2013 Mar 13.

PMID:
23499579
21.

Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope.

Matthews PC, Koyanagi M, Kløverpris HN, Harndahl M, Stryhn A, Akahoshi T, Gatanaga H, Oka S, Juarez Molina C, Valenzuela Ponce H, Avila Rios S, Cole D, Carlson J, Payne RP, Ogwu A, Bere A, Ndung'u T, Gounder K, Chen F, Riddell L, Luzzi G, Shapiro R, Brander C, Walker B, Sewell AK, Reyes Teran G, Heckerman D, Hunter E, Buus S, Takiguchi M, Goulder PJ.

J Virol. 2012 Dec;86(23):12643-54. doi: 10.1128/JVI.01381-12. Epub 2012 Sep 12.

22.

Identification of conserved subdominant HIV Type 1 CD8(+) T Cell epitopes restricted within common HLA Supertypes for therapeutic HIV Type 1 vaccines.

Karlsson I, Kløverpris H, Jensen KJ, Stryhn A, Buus S, Karlsson A, Vinner L, Goulder P, Fomsgaard A.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1434-43. doi: 10.1089/AID.2012.0081. Epub 2012 Aug 14.

PMID:
22747336
23.

Identification of a novel UTY-encoded minor histocompatibility antigen.

Mortensen BK, Rasmussen AH, Larsen ME, Larsen MV, Lund O, Braendstrup P, Harndahl M, Rasmussen M, Buus S, Stryhn A, Vindeløv L.

Scand J Immunol. 2012 Aug;76(2):141-50. doi: 10.1111/j.1365-3083.2012.02708.x.

24.

Humoral and cellular CMV responses in healthy donors; identification of a frequent population of CMV-specific, CD4+ T cells in seronegative donors.

Loeth N, Assing K, Madsen HO, Vindeløv L, Buus S, Stryhn A.

PLoS One. 2012;7(2):e31420. doi: 10.1371/journal.pone.0031420. Epub 2012 Feb 7.

25.

HLA-B*57 Micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune control.

Kloverpris HN, Stryhn A, Harndahl M, van der Stok M, Payne RP, Matthews PC, Chen F, Riddell L, Walker BD, Ndung'u T, Buus S, Goulder P.

J Virol. 2012 Jan;86(2):919-29. doi: 10.1128/JVI.06150-11. Epub 2011 Nov 16.

26.

Wildtype p53-specific antibody and T-cell responses in cancer patients.

Pedersen AE, Stryhn A, Justesen S, Harndahl M, Rasmussen S, Donskov F, Claesson MH, Pedersen JW, Wandall HH, Svane IM, Buus S.

J Immunother. 2011 Nov-Dec;34(9):629-40. doi: 10.1097/CJI.0b013e3182281381.

PMID:
21989411
27.

HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703.

Matthews PC, Adland E, Listgarten J, Leslie A, Mkhwanazi N, Carlson JM, Harndahl M, Stryhn A, Payne RP, Ogwu A, Huang KH, Frater J, Paioni P, Kloverpris H, Jooste P, Goedhals D, van Vuuren C, Steyn D, Riddell L, Chen F, Luzzi G, Balachandran T, Ndung'u T, Buus S, Carrington M, Shapiro R, Heckerman D, Goulder PJ.

J Immunol. 2011 May 15;186(10):5675-86. doi: 10.4049/jimmunol.1003711. Epub 2011 Apr 15.

28.

Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.

Wang M, Tang ST, Stryhn A, Justesen S, Larsen MV, Dziegiel MH, Lewinsohn DM, Buus S, Lund O, Claesson MH.

Immunology. 2011 Apr;132(4):482-91. doi: 10.1111/j.1365-2567.2010.03383.x. Epub 2011 Feb 7.

29.

Genome-based in silico identification of new Mycobacterium tuberculosis antigens activating polyfunctional CD8+ T cells in human tuberculosis.

Tang ST, van Meijgaarden KE, Caccamo N, Guggino G, Klein MR, van Weeren P, Kazi F, Stryhn A, Zaigler A, Sahin U, Buus S, Dieli F, Lund O, Ottenhoff TH.

J Immunol. 2011 Jan 15;186(2):1068-80. doi: 10.4049/jimmunol.1002212. Epub 2010 Dec 17.

30.

HLArestrictor--a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides.

Erup Larsen M, Kloverpris H, Stryhn A, Koofhethile CK, Sims S, Ndung'u T, Goulder P, Buus S, Nielsen M.

Immunogenetics. 2011 Jan;63(1):43-55. doi: 10.1007/s00251-010-0493-5. Epub 2010 Nov 16.

PMID:
21079948
31.

Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.

Larsen ME, Kornblit B, Larsen MV, Masmas TN, Nielsen M, Thiim M, Garred P, Stryhn A, Lund O, Buus S, Vindelov L.

Biol Blood Marrow Transplant. 2010 Oct;16(10):1370-81. doi: 10.1016/j.bbmt.2010.03.022. Epub 2010 Mar 28.

32.

Peptide specific expansion of CD8(+) T cells by recombinant plate bound MHC/peptide complexes.

Schmidt EG, Buus S, Thorn M, Stryhn A, Leisner C, Claesson MH.

J Immunol Methods. 2009 Jan 1;340(1):25-32. doi: 10.1016/j.jim.2008.09.020. Epub 2008 Oct 23.

PMID:
18950635
33.

Measurement of peptide-MHC interactions in solution using the spin column filtration assay.

Buus S, Lise Lauemøller S, Stryhn A, Østergaard Pedersen L.

Curr Protoc Immunol. 2001 May;Chapter 18:Unit 18.4. doi: 10.1002/0471142735.im1804s31.

PMID:
18432746
34.

One-pot, mix-and-read peptide-MHC tetramers.

Leisner C, Loeth N, Lamberth K, Justesen S, Sylvester-Hvid C, Schmidt EG, Claesson M, Buus S, Stryhn A.

PLoS One. 2008 Feb 27;3(2):e1678. doi: 10.1371/journal.pone.0001678.

35.

Rapid and sustained CD4(+) T-cell-independent immunity from adenovirus-encoded vaccine antigens.

Holst PJ, Bartholdy C, Stryhn A, Thomsen AR, Christensen JP.

J Gen Virol. 2007 Jun;88(Pt 6):1708-16.

PMID:
17485530
36.

CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening.

Wang M, Lamberth K, Harndahl M, Røder G, Stryhn A, Larsen MV, Nielsen M, Lundegaard C, Tang ST, Dziegiel MH, Rosenkvist J, Pedersen AE, Buus S, Claesson MH, Lund O.

Vaccine. 2007 Apr 12;25(15):2823-31. Epub 2006 Dec 29.

PMID:
17254671
37.

Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis.

Bennekov T, Dietrich J, Rosenkrands I, Stryhn A, Doherty TM, Andersen P.

Eur J Immunol. 2006 Dec;36(12):3346-55.

38.
39.
40.

Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis.

Bartholdy C, Olszewska W, Stryhn A, Thomsen AR, Openshaw PJ.

J Gen Virol. 2004 Oct;85(Pt 10):3017-26.

PMID:
15448365
41.

Incomplete effector/memory differentiation of antigen-primed CD8+ T cells in gene gun DNA-vaccinated mice.

Bartholdy C, Stryhn A, Hansen NJ, Buus S, Thomsen AR.

Eur J Immunol. 2003 Jul;33(7):1941-8.

42.

The virus-encoded chemokine vMIP-II inhibits virus-induced Tc1-driven inflammation.

Lindow M, Nansen A, Bartholdy C, Stryhn A, Hansen NJ, Boesen TP, Wells TN, Schwartz TW, Thomsen AR.

J Virol. 2003 Jul;77(13):7393-400.

43.

Role of CD28 co-stimulation in generation and maintenance of virus-specific T cells.

Christensen JE, Christensen JP, Kristensen NN, Hansen NJ, Stryhn A, Thomsen AR.

Int Immunol. 2002 Jul;14(7):701-11.

PMID:
12096029
44.

Quantitative predictions of peptide binding to MHC class I molecules using specificity matrices and anchor-stratified calibrations.

Lauemøller SL, Holm A, Hilden J, Brunak S, Holst Nissen M, Stryhn A, Østergaard Pedersen L, Buus S.

Tissue Antigens. 2001 May;57(5):405-14.

PMID:
11556965
45.

High-throughput polymerase chain reaction cleanup in microtiter format.

Hansen NJ, Pedersen LO, Stryhn A, Buus S.

Anal Biochem. 2001 Sep 1;296(1):149-51. No abstract available.

PMID:
11520046
46.

Phage display of peptide / major histocompatibility class I complexes.

Vest Hansen N, Ostergaard Pedersen L, Stryhn A, Buus S.

Eur J Immunol. 2001 Jan;31(1):32-8.

PMID:
11169435
47.

Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism.

Stryhn A, Pedersen LO, Holm A, Buus S.

Eur J Immunol. 2000 Nov;30(11):3089-99.

48.
49.

Modeling the interactions of a peptide-major histocompatibility class I ligand with its receptors. I. Recognition by two alpha beta T cell receptors.

Rognan D, Stryhn A, Fugger L, Lyngbaek S, Engberg J, Andersen PS, Buus S.

J Comput Aided Mol Des. 2000 Jan;14(1):53-69.

PMID:
10702925
50.

Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.

Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E.

Cancer Res. 2000 Feb 1;60(3):722-7.

Supplemental Content

Loading ...
Support Center